Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Maurizio Brausi, Jorg Oddens*, Richard Sylvester, Aldo Bono, Cees van de Beek, George van Andel, Paolo Gontero, Levent Turkeri, Sandrine Marreaud, Sandra Collette, Willem Oosterlinck

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)69-76
JournalEuropean Urology
Volume65
Issue number1
DOIs
Publication statusPublished - Jan 2014

Keywords

  • Urothelial carcinoma
  • Non-muscle-invasive bladder cancer
  • Maintenance BCG
  • Dose reduction
  • Side effects

Cite this